Bicara Therapeutics is focused on developing innovative therapies that harness the power of the immune system to treat cancer. The company employs a proprietary platform that combines its expertise in immuno-oncology with advanced protein engineering techniques. This approach aims to create bispecific antibodies that can simultaneously engage multiple targets on cancer cells, enhancing the immune response and improving therapeutic efficacy. By leveraging these technologies, Bicara Therapeutics seeks to address the limitations of current cancer treatments and provide more effective options for patients.

In addition to its bispecific antibody platform, Bicara Therapeutics is also exploring the potential of its proprietary drug candidates in various cancer indications. The company’s pipeline includes several promising candidates that are designed to activate immune responses specifically against tumors while minimizing off-target effects. This targeted approach not only aims to improve patient outcomes but also strives to reduce the side effects commonly associated with traditional cancer therapies. Through its innovative technologies and commitment to advancing cancer treatment, Bicara Therapeutics is positioned to make significant contributions to the field of immuno-oncology.

United States

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy

Cancer

Bicara Therapeutics

Cutaneous squamous cell carcinoma

Head and neck squamous cell carcinoma

BCA101

Biologics

<p class="font_7">Ficerafusp alfa (BCA101) is a first-in-class, dual-action, bifunctional EGFR/TGF-β antibody in clinical development for multiple different solid tumor cancer types.</p>

Bicara Therapeutics

Company Details